NCT07172867View on ClinicalTrials.gov

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Diabetes Mellitus, Type 2Obesity
Interventions
DRUG

HT-6184

2mg QD

DRUG

HT-6184 Matching Placebo

2mg QD

DRUG

Semaglutide 1 mg

Semaglutide 1 mg, every week

Sponsors
All Listed Sponsors
lead

Halia Therapeutics, Inc.

INDUSTRY